3.0 T MRI与CT对肝脏肿瘤射频消融术后局部疗效评价的比较  

Evaluation of local efficacy of ablation of liver tumor on 3. 0 T MRI and CT

作　　者：尹娜[1] 郭震[1] 付金凤 张磊[1] 王梦茹 沈文荣[1] 张晋[1] YIN Na;GUO Zhen;FU Jinfeng;ZHANG Lei;WANG Mengru;SHEN Wenrong;ZHANG Jin(CT Room,Jiangsu Province Tumor Hospital,Nanjing 210009,China)

机构地区：[1]江苏省肿瘤医院CT室,江苏南京210009

出　　处：《现代医学》2020年第3期311-316,共6页Modern Medical Journal

基　　金：江苏省卫生健康委保健局课题(BJ19032)。

摘　　要：目的:探讨肝脏肿瘤射频消融术后3.0 T MRI及CT在消融病灶疗效评估与随访中的应用。方法:回顾性分析2017年12月至2018年6月本院收治的75例行射频消融术肝脏恶性肿瘤患者的临床及影像学资料。所有患者术后均行肝脏多层螺旋CT及3.0 T MRI检查,根据改良实体瘤疗效评价标准(mRECIST),应用受试者工作特征曲线(ROC曲线)分析两种不同影像学检查对射频消融术后局部疗效评价的价值。结果:CT和3.0 T MRI诊断肝脏肿瘤消融术后肿瘤局部疗效的ROC曲线下面积分别为0.733和0.917。CT图像评价肿瘤局部疗效的敏感度、特异度、准确度分别为86.7%、60%、81%,3.0 T MRI的分别为93.3%、90%、96%。结论:3.0 T MRI在评估行肿瘤射频消融术后局部疗效方面明显优于CT,能准确且及时地对病灶进行评估,对疾病的诊疗和预后有重要的临床意义。Objective: To explore the application of 3.0 T MRI and CT in the evaluation and follow-up of ablation focus of liver tumor after radiofrequency ablation.Methods: The clinical and imaging data of 75 patients with liver cancer treated by RFA from December 2017 to June 2018 were analyzed retrospectively.All patients underwent MSCT and MRI after operation.According to the mRECIST(modified Response Evaluation Criteria in Solid Tumors),ROC(Receiver Operating Characteristic) were used to analyze the value of two different imaging examinations for local efficacy after radiofrequency ablation.Results: The area under ROC curve of CT and MRI in the diagnosis of local curative effect of liver tumor after ablation was 0.733 and 0.917,respectively.The sensitivity,specificity and accuracy of CT images in evaluating the local curative effect of tumor were 86.7%,60% and 81%,while MRI images were 93.3%,90% and 96%,respectively.Conclusion: After radiofrequency ablation of liver cancer,MRI is superior to CT in evaluating the local effect of tumor,and can accurately and timely evaluate the focus,which has important clinical significance for the diagnosis and treatment of the disease and prognosis.

关 键 词：磁共振成像 体层摄影术 X线计算机 局部疗效 射频消融术 肝脏肿瘤 

分 类 号：R730.55[医药卫生—肿瘤] R735.7[医药卫生—临床医学]